Article
Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples.
BMC cancer - 16 Feb 2017
Weyn Christine, Van Raemdonck Sofie, Dendooven Robina, Maes Vincent, Zwaenepoel Karen, Lambin Suzan, Pauwels Patrick
Abstract excerpt
BACKGROUND: Testing for KRAS mutations in metastatic colorectal cancer (mCRC) on formalin-fixed, paraffin embedded (FFPE) tumor tissue has become standard of care. Different molecular methods exist to determine hotspot KRAS mutations in exon 2, 3 and 4, but testing is often limited by the sensitivity and the speed of analysis. The aim of this retrospective study was to establish the clinical performance of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
